FDA expands Pluvicto’s metastatic castration-resistant prostate cancer indication ++

FDA expands Pluvicto’s metastatic castration-resistant prostate cancer indication https://www.fda.gov/drugs/resources-information-approved-drugs/fda-expands-pluvictos-metastatic-castration-resistant-prostate-cancer-indication FDA approves durvalumab for muscle invasive bladder cancer https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-durvalumab-muscle-invasive-bladder-cancer